Follow the entities shaping the evidence.

…feron-gamma release assay and providing 3 months of once-weekly isoniazid and rifapentine (3HP) was US$48 ($25–$82) and US$67 ($43–$101),…

…Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multiorg…

…red with interferon β-1a, reduces disability progression during secondary progressive multiple sclerosis.…

…L), statin use was associated with a 13% reduction in all-cause dementia risk and a 12% decrease in ADRD risk compared with non-users.Co…

…and those without, including immunotherapy-treated persons with lung cancer without CIP (immune checkpoint inhibitor, ICI group) and patien…

…Background The link between multiple sclerosis (MS) and Epstein-Barr virus (EBV) is well established in adults…

…ruritus), and neonatal outcomes (Apgar scores).Results Opioids (fentanyl, sufentanil) provided rapid analgesia (onset <20 minutes) but i…

…pproach, with multiple techniques documented in the literature. Spina bifida, a congenital neural tube defect, presents unique anesthetic ch…

…n of 159.9 µg/L [123.85;281.65].Conclusions Chronic intrathecal bupivacaine infusion at clinically relevant doses results in minimal system…

…he United States Food and Drug Administration recently approved Suzetrigine, a first-in-class, non-opioid, highly selective NaV1.8 pain sig…

…ogress of RA use in CS over a 10-year period (2014–2023) at the General Hospital of Rhodes (GHR), the largest hospital and primary reference point in the …

…specially for breakthrough pain9 11–13; epinephrine9 11–13; and neostigmine.11–13 Mainly due to associated adverse effects, these are not r…